ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $672,054 | +18.3% | 7,177 | +12.8% | 0.04% | +21.6% |
| Q2 2023 | $567,897 | -8.9% | 6,363 | +9.4% | 0.04% | -14.0% |
| Q1 2023 | $623,591 | -7.7% | 5,816 | +5.2% | 0.04% | -15.7% |
| Q4 2022 | $675,256 | +21.4% | 5,529 | +2.5% | 0.05% | +10.9% |
| Q3 2022 | $556,000 | +11.4% | 5,393 | +0.4% | 0.05% | -8.0% |
| Q2 2022 | $499,000 | -20.8% | 5,369 | 0.0% | 0.05% | -7.4% |
| Q1 2022 | $630,000 | -25.0% | 5,369 | -14.1% | 0.05% | -21.7% |
| Q4 2021 | $840,000 | +9.8% | 6,251 | +30.1% | 0.07% | +9.5% |
| Q3 2021 | $765,000 | +21.2% | 4,804 | 0.0% | 0.06% | 0.0% |
| Q2 2021 | $631,000 | +14.7% | 4,804 | +12.4% | 0.06% | +6.8% |
| Q1 2021 | $550,000 | +1.1% | 4,275 | +30.9% | 0.06% | -11.9% |
| Q4 2020 | $544,000 | +30.1% | 3,267 | +20.6% | 0.07% | +11.7% |
| Q3 2020 | $418,000 | +11.5% | 2,710 | +6.7% | 0.06% | +1.7% |
| Q2 2020 | $375,000 | +83.8% | 2,540 | +39.6% | 0.06% | +47.5% |
| Q1 2020 | $204,000 | – | 1,820 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |